Halozyme Confirms Minimal Impact from Medicare Guidance

An announcement from Halozyme ( (HALO) ) is now available.

On October 14, 2025, Halozyme Therapeutics issued a statement regarding the U.S. Centers for Medicare & Medicaid Services’ final IPAY 2028 guidance for Medicare price negotiations. The statement highlights that the guidance will have zero to minimal impact on the company’s future royalty revenues from ENHANZE® partner products through at least 2035. Halozyme’s research demonstrates significant cost savings and clinically meaningful benefits of subcutaneous (SC) delivery over intravenous (IV) delivery, with SC delivery preferred by a majority of patients. This development reinforces Halozyme’s strong positioning in the market by showcasing the advantages of its ENHANZE® technology in reducing healthcare costs and improving patient outcomes.

The most recent analyst rating on (HALO) stock is a Sell with a $70.00 price target. To see the full list of analyst forecasts on Halozyme stock, see the HALO Stock Forecast page.

Spark’s Take on HALO Stock

According to Spark, TipRanks’ AI Analyst, HALO is a Outperform.

Halozyme’s strong financial performance and positive earnings call sentiment are the primary drivers of its high score. The technical analysis indicates strong momentum, although caution is advised due to overbought signals. The valuation is reasonable, supporting the overall positive outlook.

To see Spark’s full report on HALO stock, click here.

More about Halozyme

Halozyme Therapeutics, Inc. operates in the biotechnology industry, focusing on drug delivery technologies. The company’s primary product is the ENHANZE® drug delivery technology, which aids in the dispersion and absorption of injected therapeutic drugs, facilitating more rapid delivery and administration of higher volumes of injectable medications through subcutaneous delivery.

Average Trading Volume: 1,989,316

Technical Sentiment Signal: Strong Buy

Current Market Cap: $7.5B

Find detailed analytics on HALO stock on TipRanks’ Stock Analysis page.